<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4920">
  <stage>Registered</stage>
  <submitdate>8/04/2015</submitdate>
  <approvaldate>8/04/2015</approvaldate>
  <nctid>NCT02414737</nctid>
  <trial_identification>
    <studytitle>Ovarian Stimulation Single Injection Elonva</studytitle>
    <scientifictitle>Ovarian Stimulation Single Injection Elonva- The OSSIE Study</scientifictitle>
    <utrn />
    <trialacronym>OSSIE</trialacronym>
    <secondaryid>AU/1/2 C8B110</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infertility</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - corifollitrophin alfa

Experimental: corifollitrophin alfa - corifollitrophin alfa used as COH stimulant in IVF


Treatment: drugs: corifollitrophin alfa
use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Oocyte maturity - number of mature oocytes (metaphase II oocytes) retrieved in IVF cycle - number of mature oocytes (metaphase II oocytes) retrieved in IVF cycle</outcome>
      <timepoint>IVF cycle (2 weeks approximately)</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Undergoing a GnRH antagonist cycle of IVF as part of their personal fertility
             treatment

          -  Eligible for the use of the 150 mcg dose of Elonva according to Australian PBS
             requirements (weight &gt; 60 kg, antral follicle count &lt; 20)

          -  Intention of undergoing a fresh embryo transfer.

          -  No major sperm quality issues (ejaculate sperm concentration &gt; 5 million/ ml, motility
             &gt; 25% neat sample). ICSI for the indication of poor morphology would be acceptable for
             trial enrollment.

          -  Maternal age 18-37 years inclusive.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>37</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Low ovarian reserve (antral follicle count 2-10 mm &lt; 7, early follicular phase FSH &gt;
             10 IU/L, &lt; 4 oocytes prior IVF cycle on a dose of rFSH &gt; 150 IU).

          -  Ovarian pathology (PCOS, ovarian cyst, endometrioma, poor trans-vaginal ultrasound
             ovary access).

          -  2 or more previous cycles of IVF (stimulated cycles) in which a live birth pregnancy
             did not result, or one prior stimulated cycle of IVF and 2 or more frozen embryo
             transfer cycles without a live birth outcome (possible implantation failure).

          -  Significant pelvic pathology likely to impair embryo implantation (fibroids, polyps,
             uterine septum, hydrosalpinx).

          -  Intention to freeze all embryos with nil fresh transfer (pre-implantation genetic
             screening, oncology fertility preservation).

          -  Known renal impairment

          -  Use of a long down regulation or "flare" IVF protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Flinders Fertility - Bedford Park</hospital>
    <postcode>5042 - Bedford Park</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Flinders Fertility</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Flinders University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We would like to propose that it may be possible to use a solitary dose of Elonva
      (corifollitrophin alpha) as the sole gonadotrophin (FSH) stimulant for the vast majority of
      women undergoing IVF, assuming that it is possible that "coasting" (withholding short acting
      rFSH) from day 8 of the stimulation until trigger/ oocyte retrieval will still result in a
      significant number of mature oocytes being produced and an acceptable pregnancy rate.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02414737</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kelton Tremellen, MD PhD</name>
      <address>Flinders University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>